Weak Tumor Antigens in Colorectal Cancer
Author Information
Author(s): Christina S. Mullins, Sven Eisold, Ernst Klar, Michael Linnebacher
Primary Institution: University of Rostock
Hypothesis
Can multidrug resistance (MDR) and related proteins (MRP) serve as tumor-specific antigens for immunological targeting in colorectal carcinoma?
Conclusion
MDR and MRP proteins are weak tumor-specific antigens for colorectal carcinoma, suggesting limited effectiveness in immunotherapy.
Supporting Evidence
- Thirty HLA-A2.1 restricted peptides were selected from MDR and MRP proteins.
- T cell lines showed activation and proliferation in response to the peptides.
- Peptide-specific T cells demonstrated some cytotoxic activity against tumor cells.
Takeaway
The study looked at whether certain proteins related to drug resistance in cancer could be targeted by the immune system, but found that they are not very effective as targets.
Methodology
The study used reverse immunology to identify HLA-A2.1 restricted peptides from MDR and MRP proteins and tested their immunogenicity in T cell cultures.
Limitations
The study's findings suggest low levels of tumor cell recognition and cytotoxicity, indicating potential issues with peptide processing and presentation.
Participant Demographics
Healthy HLA-A2.1+ donors were used for T cell isolation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website